2025 POSTER PRESENTATIONS

POSTER SESSION A: Tuesday – Wednesday (morning)

A01: Formulation Strategies for Enabling “Undevelopable” Compounds, Presented by Dave M., AustinPx

A02: Identification of Covalent JNK Inhibitor, Presented by Jun C., Axcelead

A03: High-Throughput Peptide Library: Rapid Synthesis of Linear and Cyclic Peptides Without Purification Needed, Presented by Fengping X., BioDuro

A04: Exploring the Influence of Cell Surface Post-Translational Modification (Glycosylation) on the Potency of Therapeutic Targeting in Pancreatic Cancer, Presented by Jesus A., Biosensing Instrument

A05: Massively Parallel SPR-Based Fragment Screening of Kinase Arrays, Presented by Anthony G., Carterra

A06: Biophysical Characterization of MR1 (K43A)/β2M Complex, Presented by Aravinda D., Cayman Chemical Company

A07: Fragment-Based Drug Discovery (FBDD) Approach for IRAK4, Presented by Kendall M., Cayman Chemical Company

A08: Live-Cell Real-Time Step-Gradient Quantification of Drug-Target Engagement for Rapid Drug Discovery, Presented by Ivan B., CellarisBio

A09: MICRO-TAG Cell Target Engagement Platform - From Discovery to Optimization, Presented by Elmar N., CellarisBio

A10: Exploring the Impact of Water on the Stability of the Collagen Triple Helix, Presented by Dong-Hyun S., Chungnam National University

A11: Concept’s ‘D2B’ Approach to PROTAC Drug Discovery - A Streamlined Workflow for Innovative Fast Tracking of PROTACs, Presented by Chris Y., Concept Life Sciences

A12: Applying Molecular Simulations to Qualitatively Rank Degrader Designs, Presented by Trung Kien N., Cresset

A13: MAGNET Platform: Scalable Access to Novel Chemical Matter Using “Crystal Structure First” Approach and Generative AI, Presented by Serghei G., CrystalsFirst GmbH

A14: Remove Your Analysis Bottleneck—Biacore Intelligent Analysis Software™, Presented by Cynthia S., Cytiva

A15: Development of Novel Selective FPR1 Antagonist Against Neutrophil-Mediated Inflammatory Disease, Presented by Shih-Chieh Y., Development Center for Biotechnology

A16: Integral Membrane Proteins for Biophysics and Cryo-EM Applications – Case Study of the Ion Channel TrpML3, Presented by Ray B., Domainex Ltd.

A17: Using Direct-to-Biology in a Spectral Shift-PoLiPa Platform to Enable Fast Fragment Follow-Up for Adenosine A2a Antagonists, Presented by Ray B., Domainex Ltd.

A18: Leveraging Bivalent Molecules and Biophysical / Biochemical Techniques for Enhanced Therapeutic Potential, Presented by Chris M., Domainex Ltd.

A19: Structure-Based Discovery of First Inhibitors Targeting the Helicase Activity of Human PIF1, Presented by Nathalie J., Edelris SAS

A20: Rapid, Automated Synthesis of Custom Fluorinated Libraries for an NMR-Based Hit Discovery Platform, Presented by David J., eMolecules, Inc.

A21: Emerging Hit Finding Technology: High Throughput Spectral Shift (HT-SpS) for Binder and Molecular Glue Identification, Presented by Vanessa P., Eurofins Cerep

A22: Advancing Obesity Therapeutics with Functional & Binding Cell-Based Assays for GLP-1, GIP, & Glucagon, Presented by Gaurav A., Eurofins DiscoverX

A23: Comprehensive Characterization of BTK Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Non-Covalent Mechanistic Signatures, Presented by Antonia D., Eurofins Discovery

A24: The Eurofins Emerald Database: A Foundation for AI ADMET and Off-Target Liability Prediction, Presented by Carleton S., Eurofins Discovery

A25: Phenotypic-First Approach for Discovery of Targeted Protein Degraders by RaPPIDS™ Platform to Expand the Landscape of E3 Ligases, Presented by Shinya Y., FIMECS, Inc.

A26: REAL Approach to Developing CRBN Molecular Glue Libraries and E3 Ligand-Linker Conjugate Kits, Presented by Tetiana M., Harvard T.H. Chan School of Public Health

A27: Fragment-Based Screening via Bead Display: Exploiting Avidity Effects for the Identification of Low-Affinity Binders, Presented by Isuru W., Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology

A28: VAV1-Induced Proximity: Insights from Molecule Glue Profiling, Presented by Tiejun B., ICE Bioscience

A29: The NeuroDeRisk Toolbox: De-Risking Neurotoxicity in Drug Discovery, Presented by Sharon B., Inte:Ligand GmbH

A30: Addressing Challenging Targets in Early Drug Discovery: Recent Applications of LigandScout, Presented by Eric J., Inte:Ligand GmbH

A31: Enabling Rapid Hit Identification: Integrated Platforms for PROTACs and Covalent Fragments, Presented by Alina C., IRBM Science Pk SpA

A32: Fragment Libraries for FBDD, Presented by George B., Life Chemicals, Inc.

A33: Interaction Analysis with Nucleic Acids as Targets Using GCI and ITC, Presented by Charles D., Malvern Panalytical

A34: Streamlining the High Throughput Reaction (HTE) Optimization Journey Through Automation of Data Workflows, Presented by Kristie A., Mestrelab Research

A35: Handling the Big Volume NMR and LC-MS Data for Fragment-Based Hit Screening and Making the Results Ready for AI Machine Learning, Presented by Chen P., Mestrelab Research

A36: Targeted and Technology-Driven Profiling of the Molport Fragment Chemical Space, Presented by Andrea A., Molport

A38: Rapid AI Generation of Optimised Compound Designs, Guided by User Interaction, Presented by Tamsin M., Optibrium Ltd.

A39: Crystallographic Fragment Screening Facility in Korea for Structure-Based Drug Discovery, Presented by Yeon-Gil K., Pohang Accelerator Laboratory

A40: Enabling Novel Live Cell Assays with a Silicon Membrane-Based Platform for Mechanical Delivery of Impermeable Small Molecules, Peptides, and Probes to Accelerate Early Drug Discovery, Presented by Crystal T., Portal Biotechnologies

A41: A Bioluminescent and Homogeneous Assay for Monitoring GPCR-Mediated cAMP Modulation and Adenylate Cyclase Activity, Presented by Amy L., Promega Corporation

A42: Automation-Enabled Target Engagement Selectivity Screening of Small Molecule Kinase Inhibitors, Presented by Tian Y., Promega Corporation

A43: Integrated AI and Physics-Based Methodologies for In Silico Target Identification, Presented by Ha T., SandboxAQ

A44: Discovery and Characterization of Novel ULK1/2 Inhibitors and Their Ability to Degrade ATG13, Inhibit Autophagy, and Treat KRAS Mutant Cancer, Presented by Patrick H., Sanford Burnham Prebys Medical Discovery Institute

A45: Discovery and Characterization of PROTACs of Striatal-Enriched Protein Tyrosine Phosphatase (STEP) for Alzheimer’s Disease Therapeutics, Presented by Jiaqian W., Sanford Burnham Prebys Medical Discovery Institute

A46: Computational Modeling-Enabled Ligand Design for Asymmetric C(sp3)-H Diversification of Thioethers, Presented by Nikita C., Scripps Research Institute

A47: FBDD Approaches to Tackle Emerging Multi-Component Therapeutic Targets, Presented by Stephen Y., Sygnature Discovery Ltd.

A48: Developing a Phenotypic Screening Platform for DNA-Encoded Libraries in 2D Tissue Culture, Presented by Amanda N., University of California, Irvine

A49: Disulfide-Bond Disrupting Agents: Structure-Activity Relationships of Fluorinated Bioisosteres and Fluorescent Probe Design for Bioimaging, Presented by Zaafir D., University of Florida, Gainesville

A50: Structure-Based Discovery of a Novel and Selective H. Pylori Antibacterial Class, Presented by Jonah P., University of Iowa

A51: Structure-Based Development of ASH1L Inhibitors as Potent Anti-Leukemic Agents, Presented by Guang H., University of Michigan

A52: Development of PRC1 Inhibitors Employing Fragment-Based Approach and NMR-Guided Optimization, Presented by Yiwu Y., University of Michigan

A53: Allosteric Discovery by Design: Accelerated Small Molecule Discovery with High-Throughput Microfluidics for Parallelized Enzyme Assays and Affinity Selections, Presented by Daniel M., Velocity Bio, Inc.

A54: Advancing Chemistry and Biology: An Overview of Te Kāuru—Ferrier Research Institute, Presented by Anushka J., Wellington Univentures

A55: Mirror-Image RNA-Targeted DEL Screens, Presented by Zhen C., X-Chem, Inc.

A56: Recent Trends, Limitations, and New Opportunities in Covalent Drug Discovery, Presented by Jeffrey S., X-Chem, Inc.

A57: Design and Synthesis of Novel CRBN Ligands and Rigid Linker for TPD Discovery, Presented by Jin L., PharmaBlock

POSTER SESSION B: Wednesday (afternoon) – Thursday

B01: Novel Small Molecule Inhibitors of E3 Ligase ITCH Identified by DNA-Encoded Chemical Libraries, Presented by Sarathy KP., AbbVie, Inc.

B02: Discovery and Characterisation of a Novel TRPML1 Agonist, Presented by Angelo P., BioAscent Discovery Ltd.

B03: Exploring the Power of Structural Biology on Degrader Discovery, Presented by Weijing G., Biortus

B04: Increasing DNA Encoded Library Screening Resolution Using HT-SPR, Presented by Josh E., Carterra

B05: Selectivity and Cooperativity of PROTAC®s Using HT-SPR, Presented by Anthony G., Carterra

B06: MICRO-TAG: A Novel Fluorescence-Based Real-Time Cellular Target Engagement Platform for Drug Discovery, Presented by Ivan B., CellarisBio

B07: Combined Application of CRISPR and MICRO-TAG Cell Target Engagement for Discovery of a Novel CHD4 Inhibitor in Therapy-Resistant Gliomas, Presented by Elmar N., CellarisBio

B08: Approach to Rational Identification of Lead Molecular Glue Degraders for Casein Kinase 1α, Presented by Steven Z., Chempartner

B09: A Novel Kinase Inhibitor Design Platform Based on Topological Water Networks, Presented by Re Gin J., Chungnam National University

B10: Structure-Based Drug Design of Selective Inhibitors to Target PCNA Function in Solid and Liquid Cancers, Presented by Jennifer J., City of Hope Medical Center

B11: Introducing BioPALS – A Versatile Hit Identification Technology Powered by AI and Enabled by GCI, Presented by Chris Y., Concept Life Sciences

B12: Accelerating Discovery Success with Structure-Guided Drug Design: A Worked Example from a Challenging DNA-Repair Target, Artemis, Presented by Douglas K., Curia

B13: DEL-Pilot: A Diverse and Affordable 5 Billion Compound Library Pool to Enable Hit Discovery for Your Program, Presented by Svetlana B., DEL Source

B14: Fast-Tracking Covalent Drug Discovery with AI-Powered CovScan Platform, Presented by Ghotas E., DEL Source

B15: Characterisation of Reversible and Irreversible Covalent Inhibitors Using a Novel LC-MS Based Covalent Fragment Screening Workflow, Presented by Chris M., Domainex Ltd.

B16: Synple 4.0 Discovery Platform: Automated Synthesis of Protein Degraders for Drug Discovery, Presented by David J., eMolecules, Inc.

B17: Integrated Solutions for STAT Inhibition and Targeted Protein Degradation: Enabling Novel Therapies for Cancer, Inflammation and Autoimmune Disease, Presented by Jean B., Eurofins Discovery

B18: The Discovery of Novel E3 Ligase Ligands with Proximers, Presented by James L., Evolvus

B19: Structural Insights into TEAD Inhibition: Targeting the Lipid-Binding Pocket for Cancer Therapy, Presented by Gladys B., Genentech, Inc.

B20: Identifying MARK4 Inhibitors Using RxnFlow - A Target-Oriented Synthesizable Molecule Generation Model, Presented by Sang-Yeon H., HITS Co., Ltd.

B21: Integration of AI-Optimized Design and Synthesis Toward the Identification of PKMYT1 Inhibitors, Presented by Matthew M., IKTOS

B22: Application of Vision Transformers to Protein-Ligand Affinity Prediction, Presented by Jakub P. & Pawel S., Institute of Biochemistry and Biophysics of the Polish Academy of Sciences

B23: A Generative Evolutionary Many-Objective Framework for de novo Drug Design, Presented by Isabella G., Laboratorio Nacional de Computacao Cientifica (LNCC)

B24: Fragment Based Ligand Generation Guided by Geometric Deep Learning, Presented by Helen Y., Lawrence Berkeley National Laboratory

B25: Advanced PPI-Targeting Screening Libraries, Presented by Vasily P., Life Chemicals, Inc.

B26: Ultra-High-Throughput Biophysical Screening of MEK1 Using the Dianthus uHTS Platform, Presented by Nathan A., NanoTemper Technologies, Inc.

B27: Identification of a Submicromolar BRD4 PROTAC Degrader from a Moderately Potent DEL Hit: Harnessing the Synergy of DEL & PROTAC Technologies, Presented by Laurent S., Novalix

B28: Application of Deep Learning Imputation to Peptide Bioactivity and Property Prediction, Presented by Chris K., Optibrium Ltd.

B29: Macrocyclic Peptide Optimisation: Integrating Computational Approaches with Biophysical Data, Presented by Tamsin M., Optibrium Ltd.

B30: Enhancing Primary Screening with CETSA®, Presented by Julia P., Pelago Bioscience AB

B31: Next-Generation Tools for Kinetic TPD Assays: Improving Live-Cell Analysis, Presented by Steven E., Promega Corporation

B32: De-Risking CRBN-Recruiting Degraders: Characterizing Neosubstrate Degradation Specificity and Selectivity, Presented by Alissa K., Promega Corporation

B33: Live Cell NanoBRET® TE Assays for WRN and Synthetic Lethal Targets in the DNA Damage Response Pathway, Presented by Kelly T., Promega Corporation

B34: The NanoBRET® TE Intracellular EGFR Assay: A Quantitative Assay to Determine Target Engagement to Dimeric, Membrane-Localized EGFR in Live Cells, Presented by James V., Promega Corporation

B35: Allosteric Targeting of Viral Processing Proteinases of West Nile, Zika, Dengue and Hepatitis C Viruses Using Q-MOL In Silico Drug Discovery Platform, Presented by Anton C., Q-MOL LLC

B36: Development of Biochemical Assay Tools to Enhance Drug Discovery Efforts Targeting RNA Modification Regulators, Presented by Safnas AS., Reaction Biology Corporation

B37: Next Generation Physics-Based Scoring Function Unlocks Superior ML Driven Chemical Space Exploration, Presented by Victor SP., SandboxAQ

B38: Comprehensively Benchmarking AQFEP: Assessing the Accuracy and Generalizability Across Diverse Chemical Space, Presented by Lauren W., SandboxAQ

B39: Automation of Multiplex Biochemical Assays to Enhance Productivity and Reduce Cycle Time Using a Modular Robotic Platform, Presented by Bruce T., Sanofi

B40: AlphaFold-RandomWalk: A Computational Pipeline to Sample Alternative Protein Conformations, Presented by Ishan T., Scripps Research Institute

B41: Unlocking the Power of Open DEL Libraries: A Scalable Data Analysis Platform, Presented by Helen V., Septerna

B42: CHARMED in Action: Combinatorial High-Throughput Assembly and Review of Molecular Degraders, Presented by Stephen Y., Sygnature Discovery Ltd.

B43: Total Synthesis of LXB4 and Related Chemical Probe Analogs for Target Deconvolution, Presented by Frank L., University Health Network

B44: DEL in a Gel: Activity-Based DNA-Encoded Library Screening at the Attomole Scale with Magnetic Hydrogel Particles, Presented by John B., University of California, Irvine

B45: Ligand-First vs Electrophile-First Approaches to Target His and Lys with Aryl-Fluorosulfates: Applications to hMcl-1, Presented by Giulia A., University of California, Riverside

B46: Targefrin: Targeting Metastases and Targeted Delivery of Chemo and/or Radiation, Presented by Carlo B., University of California, Riverside

B47: Stabilized β-Hairpins as PPI Ligands: Applications to EphA4 and MDM2, Presented by Anne Marie P., University of California, Riverside

B48: Lysine Reactive Probes for the PHD3 Domain of KDM5A, Presented by Darius M., University of California, San Francisco

B49: Molecular Dynamics Simulations of Metabolite and Peptide Fibrils, Presented by Pavel R., University of Illinois at Chicago

B50: Kinome-Wide Virtual Screening via Multi-Task Deep Learning for Small Molecular Drug Discovery in Cancer, Presented by Jiaming H., University of Miami

B51: Targeted DEL Platforms: Cell-Permeable Peptide–Small Molecule Libraries for Undruggable Cancer Targets, Presented by Jay L., University of North Carolina at Chapel Hill

B52: Selective Drug Discovery via Highly Parallelized DEL Screening, Presented by Matthew K., Velocity Bio, Inc.

B53: DELs in Cells – Direct Screening for Molecular Glue, Presented by Leif L., Vipergen Aps

B54: Development of Next Generation Inhibitors to Disrupt C-Terminal Binding Protein's Oncogenic Effects, Presented by Nicholette S., Virginia Commonwealth University

B55: One Stop DEL Solution: Viva‘s High-Value, High-Capability DNA-Encoded Library Platform, Presented by Yinghong G., Viva Biotech Ltd.

B56: Discovery of Pks13 Inhibitors for the Treatment of Tuberculosis (TB) Through DNA-Encoded Chemical Library (DEL) Screening, Presented by Ananta G., X-Chem, Inc.

ADDITIONAL VIRTUAL POSTERS

V1: An NMR-Based Fragment Screening Approach to Identify LCAT Modulators, Presented by Elena H., National Institutes of Health, National Center for Advancing Translational Sciences

V2: Use of Virtual Screening and In Vitro Assays to Identify Small Molecules for Their Potential Treatment of Opioid Tolerance, Presented by Masato O., National Institutes of Health, National Center for Advancing Translational Sciences